Measured dose rate constant from oncology patients administered 18F for positron emission tomography

2012 ◽  
Vol 39 (10) ◽  
pp. 6071-6079 ◽  
Author(s):  
Brian Quinn ◽  
Brian Holahan ◽  
Jean Aime ◽  
John Humm ◽  
Jean St. Germain ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Dose Rate ◽  
Rate Constant ◽  
Emission Tomography ◽  
Oncology Patients ◽  
Positron Emission ◽  
Measured Dose

68Ga-DOTATOC

2021 ◽  
Vol 70 (4) ◽  
pp. 136-141
Author(s):  
Michal Budinský ◽  
Petr Vyšinský ◽  
Stanislav Synek ◽  
Beatrix Bencsiková ◽  
Iveta Selingerová ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Quality Control ◽  
Neuroendocrine Tumor ◽  
Somatostatin Receptor ◽  
Emission Tomography ◽  
Oncology Patients ◽  
Positron Emission

The radiopharmaceutical 68Ga-DOTATOC represents the latest radiopharmaceutical in the diagnosis of a neuroendocrine tumor with somatostatin receptor overexpression. Technological and economic difficulties of preparing and quality control of the radiopharmaceutical limit its use to specialised departments. Background of the department with rich experience with radiopharmaceuticals for positron emission tomography allows handling more difficult 68Ga-radiopharmacy and may increase and improve the care of oncology patients.

Sign in / Sign up

Export Citation Format

Share Document